Advocacy In Action: Who Should Have Molecular Testing When Diagnosed With Lung Cancer?
Description: Vital Options International presents, Advocacy In Action®, bringing together cancer advocacy leadership to address: Lung Cancer Treatment Guidelines & Molecular Testing.
This segment asks the question: Why are only EFR and ALK are tested for and who should be tested?
Joining Selma Schimmel as co-moderators are:
David R. Spigel, MD - Director, Lung Cancer Research Program at Sarah Cannon Research Institute and a Medical Oncologist at Tennessee Oncology, PLLC, Nashville, TN
Ming S. Tsao, MD, FRCPC - Princess Margaret Cancer Centre, Toronto, Canada
Susan Mantel - VP Programs & Marketing, LUNGevity
Kim Norris - Founder/President, Lung Cancer Foundation of America
Regina Vidaver, PhD - Executive Director, National Lung Cancer Partnership
Shared By : vitaloptions
Posted on : 07/09/13
Added : 6 years ago